This product is a human IgG1, κ antibody that can recognize human TNFRSF8.
Host: Human
Isotype: Human IgG1, κ
Applications: Neut, ELISA, IF, IP, FuncS, FC, ICC
Figure 1 Brentuximab vedotin blocks proliferation of PEL cells.
Human PEL cell lines BC-1 (A), BC-3 (B), UM-PEL-1c (C), and UM-PEL-3c (D) were treated with brentuximab vedotin (B.V.) at indicated doses for 0, 24, 48, and 72 hours. Proliferative response at each time point was measured by MTS assay.
Bhatt, S., Ashlock, B. M., Natkunam, Y., Sujoy, V., Chapman, J. R., Ramos, J. C.,... & Lossos, I. S. (2013). CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood, 122(7), 1233-1242.
Figure 2 Rentuximab vedotin induces G2/M cell cycle arrest of PEL cells.
PEL cell lines BC-1 (A), BC-3 (B), UM-PEL-1c (C), and UM-PEL-3c (D) were treated with brentuximab vedotin (B.V.) at increasing concentrations. At 24 hours after treatment, cells were stained with propidium iodide to measure DNA content and analyzed by flow cytometry for cell cycle distribution. Bar graphs indicate the percentage of cells in different phases of cell cycle (G0, G1, S, G2/M).
Bhatt, S., Ashlock, B. M., Natkunam, Y., Sujoy, V., Chapman, J. R., Ramos, J. C.,... & Lossos, I. S. (2013). CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood, 122(7), 1233-1242.
Figure 3 Brentuximab vedotin triggers apoptosis of PEL cells.
Lymphoma cell lines lacking CD30 expression WSU-NHL (A) and Raji (B) and CD30-expressing PEL cell lines BC-1 (C), BC-3 (D), UM-PEL-1c (E), and UM-PEL-3c (F) were treated with increasing concentrations of brentuximab vedotin (B.V.) or Ig-VcMMAE. At 72 hours after treatment, cell viability was determined by flow cytometry following YO-PRO and propidium iodide staining.
Bhatt, S., Ashlock, B. M., Natkunam, Y., Sujoy, V., Chapman, J. R., Ramos, J. C.,... & Lossos, I. S. (2013). CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood, 122(7), 1233-1242.
Figure 4 CD30 levels, CD30 internalization, and brentuximab vedotin cell surface binding.
(A) sCD30 levels measured by ELISA in indicated cell lines and in cells directly derived from mice ascites. Error bar represents standard error of the mean between triplicate wells. (B) Cell surface CD30 expression and (C) cell surface brentuximab vedotin binding. BC-3, UM-PEL-1c, UM-PEL-3c, and Karpas 299 cells were incubated with 15 μg/mL brentuximab vedotin for 0, 24, and 48 hours followed by incubation with anti-CD30 (fluorescein isothiocyanate [FITC]) (B) or anti-hIgG (FITC) (C) to determine antigen-binding capacity values for CD30 (B) and of bound brentuximab vedotin (C), respectively.
Bhatt, S., Ashlock, B. M., Natkunam, Y., Sujoy, V., Chapman, J. R., Ramos, J. C.,... & Lossos, I. S. (2013). CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood, 122(7), 1233-1242.
Figure 5 Brentuximab vedotin extends the survival of PEL xenograft mice.
Kaplan-Meier survival curves of PEL xenograft mice. NOD/SCID mice (n = 5/group) were injected with 25 × 106 UM-PEL-1 (A) and UM-PEL-3 (B) cells. At 3 days postinjection, mice were treated for 3 weeks with interperitoneal injections of brentuximab vedotin (B.V.), PBS, or isotype-matched irrelevant Ig-vcMMAE.
Bhatt, S., Ashlock, B. M., Natkunam, Y., Sujoy, V., Chapman, J. R., Ramos, J. C.,... & Lossos, I. S. (2013). CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood, 122(7), 1233-1242.
Figure 6 Brentuximab vedotin reduces viable cell number in CD30-positive but not CD30-negative GCT cells.
The CD30-positive EC cell lines GCT27 and NCCIT as well as the CD30-negative choriocarcinoma line JAR were treated with MMAE (A) or brentuximab vedotin (B-D). GCT27 (B), JAR (C) and NCCIT (D) were exposed to 250 ng/ml brentuximab vedotin. After 24, 48, 72 and 96 hrs of culture, cells were resuspended in equal volume for analysis. Viable Hoechst-negative cells were enumerated for 180 sec. by flow cytometry and are represented as multiples (x-fold) of the untreated control obtained at 24 hrs. To further evaluate dose-dependent effects to brentuximab vedotin, the three cell lines were exposed for 96 hrs to 250, 500 and 1000 ng/ml of the ADC as well as 100 pM MMAE (E). Enumerated viable Hoechst-negative cells are expressed in percent of the untreated control at 96 hrs.
Götz, B., van Beekum, C., Nettersheim, D., Schorle, H., Calaminus, G., Leuschner, I.,... & Schönberger, S. (2015). brentuximab Vedotin Presents Profound Anti-tumor Efficacy In Cd30+ And Co-cultured Cd30-Germ Tumor Cells: o-129. Pediatric Blood & Cancer, 62, S179.
Figure 7 Brentuximab vedotin exerts pronounced bystander activity on MMAE-sensitive, CD30-negative GCT cells in coculture with CD30-positive embryonal carcinoma.
For determination of bystander efficacy after drug exposure, cells were stained with CSFE and anti-CD30.PE (BER-H2, eBiosience/Germany). After 96 hrs of drug exposure, cell cultures were resuspended in equal volume and acquired for 180 sec. by flow cytometry. CD30-negative JAR cells are EPCAM positive (y-axis) but CD30 negative (x-axis) while GCT27 cells are EPCAM and CD30 positive. Hoechst-negative viable CD30-positive and CD30-negative subpopulations were assessed separately after gating on the respective cell fraction (A). Viable cell numbers are expressed in per cent of untreated control (B). Proliferation is investigated by CSFE dilution upon cellular division. To indicate inhibition of proliferation MFI of experimental conditions was normalized to the MFI of untreated cells and presented as x-fold MFI (C). Cell death was quantified as the proportion of Hoechstpositive cells of the entirety of acquired cells (D)
Götz, B., van Beekum, C., Nettersheim, D., Schorle, H., Calaminus, G., Leuschner, I.,... & Schönberger, S. (2015). brentuximab Vedotin Presents Profound Anti-tumor Efficacy In Cd30+ And Co-cultured Cd30-Germ Tumor Cells: o-129. Pediatric Blood & Cancer, 62, S179.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
MOB-1158z | Mouse Anti-TNFRSF8 Recombinant Antibody (clone 19C10) | WB, FC, FuncS | Mouse IgG2b |
HPAB-0445-CN | Mouse Anti-TNFRSF8 Recombinant Antibody (clone T105) | WB, ELISA, FC | Mouse IgG1 |
HPAB-0447-CN | Mouse Anti-TNFRSF8 Recombinant Antibody (clone T405) | WB, ELISA | Mouse IgG2b |
HPAB-0459-WJ | Mouse Anti-TNFRSF8 Recombinant Antibody (HPAB-0459-WJ) | ELISA, FuncS | Mouse IgG |
FAMAB-0358WJ | Human Anti-TNFRSF8 Recombinant Antibody (clone AK30) | ELISA, WB | Human IgG |
CAT | Product Name | Application | Type |
TAB-144 | Anti-Human CD30 Recombinant Antibody (Iratumumab) | ELISA, FC, IP, FuncS, IF, Neut, ICC | IgG1 - kappa |
CAT | Product Name | Application | Type |
AGTO-G062E | Anti-TNFRSF8 immunotoxin Ki-3 (scFv)-PE | Cytotoxicity assay, Function study | |
AGTO-G062R | Anti-TNFRSF8 immunotoxin Ki-3 (scFv)-RTA | Cytotoxicity assay, Function study | |
AGTO-G062S | Anti-TNFRSF8 immunotoxin Ki-3 (scFv)-Sap | Cytotoxicity assay, Function study | |
AGTO-L041E | anti-TNFRSF8 immunotoxin Ber-H2 (IgG)-PE | Cytotoxicity assay, Functional assay | |
AGTO-L041R | anti-TNFRSF8 immunotoxin Ber-H2 (IgG)-RTA | Cytotoxicity assay, Functional assay |
CAT | Product Name | Application | Type |
TAB-635CL | Human Anti-TNFRSF8 Recombinant Antibody (TAB-635CL) | ELISA | Human IgG |
TAB-102LC | Anti-Human TNFRSF8 Recombinant Antibody | WB, FC, ELISA | Humanized antibody |
TAB-103LC | Anti-Human TNFRSF8 Recombinant Antibody | WB, FC, ELISA | Humanized antibody |
TAB-102LC-S(P) | Anti-Human TNFRSF8 Recombinant Antibody scFv Fragment | WB, FC, ELISA | Humanized antibody |
TAB-103LC-S(P) | Anti-Human TNFRSF8 Recombinant Antibody scFv Fragment | WB, FC, ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
Gly-139LC | Recombinant Anti-Human TNFRSF8 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
Gly-139LC-1 | Recombinant Anti-Human TNFRSF8 Antibody (Fc glycosylation/Non fucosylated) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
BRD-0597MZ | Chicken Anti-TNFRSF8 Polyclonal IgY | WB | Chicken antibody |
CAT | Product Name | Application | Type |
NEUT-2165CQ | Hamster Anti-Tnfrsf8 Recombinant Antibody (clone mCD30.1) | FC, Stim, Costim, Block | Hamster IgG1 |
CAT | Product Name | Application | Type |
NEUT-2166CQ | Hamster Anti-Tnfrsf8 Recombinant Antibody (clone 2SH12-5F) | Neut, FC | Hamster IgG1, κ |
CAT | Product Name | Application | Type |
MOR-3617 | Rabbit Anti-TNFRSF8 Recombinant Antibody (clone DS3617AB) | WB, IHC-P | Rabbit IgG |
MOR-3618 | Rabbit Anti-TNFRSF8 Recombinant Antibody (clone DS3618AB) | ELISA | Rabbit IgG |
CAT | Product Name | Application | Type |
HPAB-0329-YC-F(E) | Mouse Anti-TNFRSF8 Recombinant Antibody; Fab Fragment (HPAB-0329-YC-F(E)) | ELISA, FC, Cyt, FuncS | Mouse Fab |
HPAB-0330-YC-F(E) | Human Anti-TNFRSF8 Recombinant Antibody; Fab Fragment (HPAB-0330-YC-F(E)) | ELISA, FC, Cyt, FuncS | Human Fab |
HPAB-0331-YC-F(E) | Mouse Anti-TNFRSF8 Recombinant Antibody; Fab Fragment (HPAB-0331-YC-F(E)) | ELISA, FC, Cyt, FuncS | Mouse Fab |
HPAB-0332-YC-F(E) | Human Anti-TNFRSF8 Recombinant Antibody; Fab Fragment (HPAB-0332-YC-F(E)) | FC, Cyt | Human Fab |
HPAB-0250-FY-F(E) | Recombinant Human Anti-TNFRSF8 Antibody Fab Fragment | F, IH | Human Fab |
CAT | Product Name | Application | Type |
HPAB-0325CQ-S(P) | Human Anti-TNFRSF8 Recombinant Antibody; scFv Fragment (HPAB-0325CQ-S(P)) | ELISA, FC, FuncS, Cyt | Humanized scFv |
HPAB-1929-FY-F(E) | Human Anti-TNFRSF8 Recombinant Antibody (clone 17G1); scFv Fragment | FC, ELISA | Human scFv |
HPAB-1930-FY-F(E) | Human Anti-TNFRSF8 Recombinant Antibody (clone 2H9); scFv Fragment | FC, ELISA | Human scFv |
HPAB-1931-FY-F(E) | Human Anti-TNFRSF8 Recombinant Antibody (clone 5F11); scFv Fragment | FC, ELISA | Human scFv |
FAMAB-0358WJ-S(P) | Human Anti-TNFRSF8 Recombinant Antibody (clone AK30); scFv Fragment | ELISA, WB | Human scFv |
CAT | Product Name | Application | Type |
AFC-TAB-144 | Afuco™ Anti-TNFRSF8 ADCC Recombinant Antibody (Iratumumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
AFC-TAB-153 | Afuco™ Anti-TNFRSF8 ADCC Recombinant Antibody (Brentuximab), ADCC Enhanced | Neut, ELISA, IF, IP, FuncS, FC | ADCC enhanced antibody |
Submit a review or a question
There are currently no Customer reviews or questions for TAB-153. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.